Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients

被引:36
作者
Fogelson, N
Kogan, E
Korczyn, AD [1 ]
Giladi, N
Shabtai, H
Neufeld, MY
机构
[1] Tel Aviv Univ, Sch Med, Sieratzki Chair Neurol, IL-69978 Ramat Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, EEG & Epilepsy Unit, Tel Aviv, Israel
[4] Tel Aviv Sourasky Med Ctr, Dept Neurol, Tel Aviv, Israel
来源
ACTA NEUROLOGICA SCANDINAVICA | 2003年 / 107卷 / 04期
关键词
Parkinson's disease; dementia; quantitative electroencephalogram; rivastigmine; cholinesterase inhibitors;
D O I
10.1034/j.1600-0404.2003.00081.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives - Quantitative electroencephalogram (qEEG) can be used to measure the effects of drugs on the brain. We studied the effects of rivastigmine on the qEEG in Parkinson's disease (PD) patients with dementia. Subjects and methods - Demented PD patients (n =19) were treated with rivastigmine in an open label study. Recordings were obtained prior to and following 12 weeks of treatment. Results were analyzed using two-way ANOVA with repeated measures. Results - A significant increase in the relative alpha (P < 0.05) activity was observed after treatment with rivastigmine. This was general rather than localized to specific brain surface areas. An increase in beta activity and decrease in the slower frequencies (delta and theta) were also observed; however, these were not statistically significant. Conclusion - qEEG may serve as an objective tool to monitor the effects of antidementia drug therapy. The changes characterized by increased faster frequencies and decreased slower frequencies that were observed may indicate increased arousal or improvement in the cognitive state of the patients as a consequence of the treatment with rivastigmine.
引用
收藏
页码:252 / 255
页数:4
相关论文
共 17 条
[1]  
ALHAINEN K, 1993, ACTA NEUROL SCAND, V88, P16
[2]   DISCRIMINATION OF TETRAHYDROAMINOACRIDINE RESPONDERS BY A SINGLE DOSE PHARMACO-EEG IN PATIENTS WITH ALZHEIMERS-DISEASE [J].
ALHAINEN, K ;
PARTANEN, J ;
REINIKAINEN, K ;
LAULUMAA, V ;
SOININEN, H ;
AIRAKSINEN, M ;
RIEKKINEN, P .
NEUROSCIENCE LETTERS, 1991, 127 (01) :113-116
[3]   Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease [J].
Giladi, N ;
Treves, TA ;
Paleacu, D ;
Shabtai, H ;
Orlov, Y ;
Kandinov, B ;
Simon, ES ;
Korczyn, AD .
JOURNAL OF NEURAL TRANSMISSION, 2000, 107 (01) :59-71
[4]  
GILADI N, IN PRESS ACTA NEUROL
[5]   Clinical neurophysiology using electroencephalography in geriatric psychiatry: Neurobiologic implications and clinical utility [J].
Holschneider, DP ;
Leuchter, AF .
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 1999, 12 (03) :150-164
[6]   ACCURACY OF CLINICAL-DIAGNOSIS OF IDIOPATHIC PARKINSONS-DISEASE - A CLINICOPATHOLOGICAL STUDY OF 100 CASES [J].
HUGHES, AJ ;
DANIEL, SE ;
KILFORD, L ;
LEES, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1992, 55 (03) :181-184
[7]   Cholinesterase inhibition in Parkinson's disease [J].
Hutchinson, M ;
Fazzini, E .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (03) :324-325
[8]   Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease [J].
Jann, MW .
PHARMACOTHERAPY, 2000, 20 (01) :1-12
[9]   Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study [J].
McKeith, I ;
Del Ser, T ;
Spano, P ;
Emre, M ;
Wesnes, K ;
Anand, R ;
Cicin-Sain, A ;
Ferrara, R ;
Spiegel, R .
LANCET, 2000, 356 (9247) :2031-2036
[10]   EEG FREQUENCY-ANALYSIS IN DEMENTED AND NONDEMENTED PARKINSONIAN-PATIENTS [J].
NEUFELD, MY ;
BLUMEN, S ;
AITKIN, I ;
PARMET, Y ;
KORCZYN, AD .
DEMENTIA, 1994, 5 (01) :23-28